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ABSTRACT 
Ximenia americana root bark (Olacaceae) and Pavetta crassipes (Rubiaceae) leaf 
used in Nigerian traditional medicine were tested individually against clinical isolate 
of Mycobacterium tuberculosis by Lowenstein - Jensen method.  Crude aqueous 
extracts of X. americana and P. crassipes exhibited minimum inhibitory activity 
(MIC) of 100 µg/mL and 200 µg/mL respectively.  
Sequential screening with solvents of different polarities was used in evaluation 
tests to readily locate the source of the activity against tuberculosis and for 
conditions related to skin diseases since it was readily available.  In general, 
antimicrobial screening of crude extracts gave MICs ranging from 31.25 µg/mL to > 
5 mg/mL, with X. americana methanol extract being most active at 31.25 µg/mL 
against Staphylococcus aureus. In an effort to determine possible mechanisms of 
action, synergistic  interaction studies between standard antibiotics and plant 
extracts were carried out with some synergy being observed between X. 
americana   extract and streptomycin. 
Hexane (MIC 60.6 µg/mL) and dichloromethane (MIC 30.5 µg/mL) fractions of X. 
americana exhibited 94.3 % and 96.4 % inhibition against M. tuberculosis H37HRv 
(virulent strain) while P. crassipes hexane fraction had 86.7% inhibition at > 64 
µg/mL. Using HPLC, TLC, GC, 1D and 2D-NMR as well as mass spectral analyses 
it was possible to identify rutin and 5-O- caffeoyl quinic acid methyl ester from P. 
crassipes. It proved extremely difficult to identify compounds from LC and TLC 
fractions from the non-polar extracts of X. americana responsible for anti-TB 
activity. There was some spectroscopic evidence from these fractions for closely 
related phytosterol esters and individual compounds such as stigmast- 3, 5 - diene, 
stigmastane oleate and β-sitosterol.  
Subsequent LC work with refractive index detection and SFC with evaporative light 
scattering data confirmed that the difficulties in assignment arose from the 
presence of non-UV absorbing non-volatile co-eluting compounds. Preparative 
xviii 
 
SFC or SFC-MS with the aid of the NIST database would have been needed for 
identification.  
Overall, these results lend some credence to the claims of the Nigerian remedy 
and potentially could be a source of assay biomarkers for monitoring its safety, 
efficacy and quality as required by IRCH (International Regulatory Co-operation for 
Herbal Medicines). 
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